145 results on '"Mossanen, M."'
Search Results
2. Defining factors associated with high-quality surgery following radical cystectomy : analysis of the British Association of Urological Surgeons cystectomy audit
3. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer
4. Genomic Features of Radiation-Associated Muscle-Invasive Bladder Cancer
5. Defining factors associated with high-quality surgery following radical cystectomy: Analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit
6. Comparison of comorbidity indices for prediction of morbidity and mortality after major surgical procedures
7. Examining the association between operative time and radical cystectomy complications
8. The natural history of sarcomatoid renal-cell carcinoma, a stage-by-stage analysis
9. Propensity score based comparison of nephroureterectomy versus segmental ureterectomy for ureteral tumors
10. Conversion to open surgery remains minimal despite growing use of laparoscopic or robotic nephrectomy
11. Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis
12. Defining factors associated with quality surgery following radical cystectomy: Analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit
13. Alvimopan is associated with a reduction in length of stay and hospital costs for patients undergoing radical cystectomy
14. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histological subtype matter?
15. Evaluating the cost of surveillance for non-muscle invasive bladder cancer: An economic analysis based on risk categories
16. Comparative Effectiveness of Bladder-Preserving Tri-Modality Therapy versus Radical Cystectomy for Muscle-Invasive Bladder Cancer
17. Perioperative outcomes of aspirin use in partial nephrectomy
18. Utilization and outcomes of chemoprophylaxis for the prevention of venous thromboembolism following radical cystectomy: A population-based study
19. Trends and morbidity for minimally invasive versus open cytoreductive nephrectomy in the management of metastatic renal cell carcinoma
20. SC171 - Conversion to open surgery remains minimal despite growing use of laparoscopic or robotic nephrectomy
21. PT415 - Defining factors associated with quality surgery following radical cystectomy: Analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit
22. 1115 - Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histological subtype matter?
23. 1009 - Alvimopan is associated with a reduction in length of stay and hospital costs for patients undergoing radical cystectomy
24. 705 - Evaluating the cost of surveillance for non-muscle invasive bladder cancer: An economic analysis based on risk categories
25. 895 - Perioperative outcomes of aspirin use in partial nephrectomy
26. 707 - Utilization and outcomes of chemoprophylaxis for the prevention of venous thromboembolism following radical cystectomy: A population-based study
27. 435 - Trends and morbidity for minimally invasive versus open cytoreductive nephrectomy in the management of metastatic renal cell carcinoma
28. P154 - AIRD1A knockouts in bladder cancer cell lines leads to MYC and E2F activation implicated in more aggressive tumor behavior.
29. A0807 - Did the COVID-19 pandemic accelerate the shift to outpatient surgery in urologic oncology? Results from a state administrative database.
30. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration
31. Factors predictive of recurrence, metastasis and death in node-negative penile squamous cell carcinoma: A retrospective multicentre cohort study.
32. Performance of VI-RADS in predicting muscle-invasive bladder cancer after transurethral resection: a single center retrospective analysis.
33. Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer.
34. Impact of smoking status on health-related quality of life (HRQoL) in cancer survivors.
35. Total Margin Control Is Superior to Traditional Margin Assessment for Treatment of Low-Stage Penile Squamous Cell Carcinoma.
36. Impact of COVID-19 pandemic on ambulatory urologic oncology surgeries.
37. Anticoagulation prophylaxis patterns following retroperitoneal lymph node dissection for testis cancer.
38. Smoking status among cancer patients by specialty: A U.S. nationwide representative analysis.
39. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
40. Bladder cancer patient and provider perspectives on smoking cessation.
41. Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder Cancer.
42. Urologists' Perceptions and Practices Related to Patient Smoking and Cessation: A National Assessment From the 2021 American Urological Association Census.
43. Comparison of Long-term Outcomes for Young and Healthy Patients with cT1a and cT3a Renal Cell Carcinoma Treated with Partial Nephrectomy.
44. Is Segmental Ureterectomy Associated with Inferior Survival for Localized Upper-Tract Urothelial Carcinoma of the Ureter Compared to Radical Nephroureterectomy?
45. Assessment of the Ecological Association between Tobacco Smoking Exposure and Bladder Cancer Incidence over the Past Half-Century in the United States.
46. The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis.
47. Association between Operative Time and Short-Term Radical Cystectomy Complications.
48. Impact of exercise on physical health status in bladder cancer patients.
49. Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes.
50. Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.